Zoetis Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
14,500
- Stock Symbol
-
ZTS
- Investments
-
34
- Share Price
-
$79.11
- (As of Friday Closing)
Zoetis General Information
Description
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Contact Information
Website
www.zoetis.comCorporate Office
- 10 Sylvan Way
- Parsippany, NJ 07054
- United States
Corporate Office
- 10 Sylvan Way
- Parsippany, NJ 07054
- United States
Zoetis Stock Performance
As of 20-Nov-2026, Zoetis’s stock price is $79.11. Its current market cap is $32.1B with 406M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $79.11 | $80.79 | $68.77 - $132.49 | $32.1B | 406M | 4.51M | $5.89 |
Zoetis Financials Summary
As of 30-Sep-2026, Zoetis has a trailing 12-month revenue of $9.5B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,420,404 | 60,641,020 | 78,553,315 | 95,605,269 |
| Revenue | 9,494,000 | 9,467,000 | 9,256,000 | 8,544,000 |
| EBITDA | 3,755,000 | 3,976,000 | 3,749,000 | 3,563,000 |
| Net Income | 2,507,000 | 2,673,000 | 2,486,000 | 2,344,000 |
| Total Assets | 15,088,000 | 15,467,000 | 14,237,000 | 14,286,000 |
| Total Debt | 9,237,000 | 9,238,000 | 6,744,000 | 6,755,000 |
Zoetis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zoetis Comparisons
Industry
Financing
Details
Zoetis Competitors (5)
One of Zoetis’s 5 competitors is Elanco Animal Health, a Corporation company based in Indianapolis, IN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Elanco Animal Health | Corporation | Indianapolis, IN | ||||
| Neogen (Lansing) | Formerly VC-backed | Lansing, MI | ||||
| Phibro Animal Health | Formerly PE-Backed | Teaneck, NJ | ||||
| Vetoquinol | Formerly PE-Backed | Lure, France | ||||
| Idexx Laboratories | Formerly VC-backed | Westbrook, ME |
Zoetis Patents
Zoetis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217876-A1 | Compositions and methods for enhancing the stability of a canine antibody | Pending | 11-Apr-2025 | ||
| WO-2026136402-A1 | Compositions and methods for improving canine antibody functions | Pending | 19-Dec-2024 | ||
| WO-2026136223-A1 | Compositions and methods for improving feline antibody functions | Pending | 19-Dec-2024 | ||
| WO-2026122475-A1 | Dna vaccine against infectious salmon anemia virus | Pending | 04-Dec-2024 | ||
| WO-2026106884-A1 | Process for preparing immunogenic azalides | Pending | 12-Nov-2024 | C07H17/08 |
Zoetis Signals
Zoetis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zoetis Investments & Acquisitions (34)
Zoetis’s most recent deal was a Merger/Acquisition with VitalRads. The deal was made on 31-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| VitalRads | 31-Jul-2026 | Merger/Acquisition | Other Services (B2C Non-Financial) | ||
| Techcyte | 30-Apr-2026 | Later Stage VC | Decision/Risk Analysis | ||
| GeneSeek | 02-Mar-2026 | Merger/Acquisition | Biotechnology | ||
| Veterinary Pathology Group | 10-Nov-2025 | Merger/Acquisition | Other Services (B2C Non-Financial) | ||
| Espuña (45,000 Square Meters Parcel of Land in La Vall de Bianya, Spain) | 01-Mar-2024 | Corporate Asset Purchase | Buildings and Property |
Zoetis ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
13.77 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Zoetis Exits (2)
Zoetis’s most recent exit was on 08-Apr-2020 from Performance Livestock Analytics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Performance Livestock Analytics | 08-Apr-2020 | Completed |
|
||
| KL Products | 06-Aug-2015 | Merger/Acquisition | Completed |
Zoetis Affiliates
Subsidiaries (9)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| PetMedix | Cambridge, United Kingdom | 2017 | |
| Basepaws | Kalamazoo, MI | 2016 | |
| NewMetrica | Glasgow, United Kingdom | 2013 | |
| Virtual Recall | Leatherhead, United Kingdom | 2011 | |
| Veterinary Pathology Group | Exeter, United Kingdom | 2001 |
Zoetis FAQs
-
When was Zoetis founded?
Zoetis was founded in 2012.
-
Where is Zoetis headquartered?
Zoetis is headquartered in Parsippany, NJ.
-
What is the size of Zoetis?
Zoetis has 14,500 total employees.
-
What industry is Zoetis in?
Zoetis’s primary industry is Other Agriculture.
-
Is Zoetis a private or public company?
Zoetis is a Public company.
-
What is Zoetis’s stock symbol?
The ticker symbol for Zoetis is ZTS.
-
What is the current stock price of Zoetis?
As of 20-Nov-2026 the stock price of Zoetis is $79.11.
-
What is the current market cap of Zoetis?
The current market capitalization of Zoetis is $32.1B.
-
What is Zoetis’s current revenue?
The trailing twelve month revenue for Zoetis is $9.5B.
-
Who are Zoetis’s competitors?
Elanco Animal Health, Neogen (Lansing), Phibro Animal Health, Vetoquinol, and Idexx Laboratories are competitors of Zoetis.
-
What is Zoetis’s annual earnings per share (EPS)?
Zoetis’s EPS for 12 months was $5.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process